NR3C1 | Nuclear receptor subfamily 3, group C, member 1 (glucocorticoid receptor) | Disease related genes FDA approved drug targets Nuclear receptors Plasma proteins Predicted intracellular proteins Transcription factors
| | | | | Expressed in all |
NR3C2 | Nuclear receptor subfamily 3, group C, member 2 | Disease related genes FDA approved drug targets Nuclear receptors Predicted intracellular proteins Transcription factors
| | | | | Expressed in all |
OPRM1 | Opioid receptor, mu 1 | FDA approved drug targets G-protein coupled receptors Predicted membrane proteins
| | | | | Tissue enhanced |
P2RY12 | Purinergic receptor P2Y, G-protein coupled, 12 | Disease related genes FDA approved drug targets G-protein coupled receptors Predicted membrane proteins
| | | | | Tissue enhanced |
PAH | Phenylalanine hydroxylase | Disease related genes Enzymes FDA approved drug targets Predicted intracellular proteins
| | | | | Group enriched |
PDE5A | Phosphodiesterase 5A, cGMP-specific | Enzymes FDA approved drug targets Predicted intracellular proteins
| | | | | Expressed in all |
PDE7A | Phosphodiesterase 7A | Enzymes FDA approved drug targets Predicted intracellular proteins Predicted secreted proteins
| | | | | Expressed in all |
PDE8B | Phosphodiesterase 8B | Disease related genes Enzymes FDA approved drug targets Predicted intracellular proteins
| | | | | Tissue enriched |
PDGFRB | Platelet-derived growth factor receptor, beta polypeptide | Cancer-related genes CD markers Disease related genes Enzymes FDA approved drug targets Plasma proteins Predicted intracellular proteins Predicted membrane proteins Predicted secreted proteins RAS pathway related proteins
| | | | | Mixed |
PGR | Progesterone receptor | Cancer-related genes FDA approved drug targets Nuclear receptors Predicted intracellular proteins Transcription factors
| | | | | Group enriched |
PLA2G1B | Phospholipase A2, group IB (pancreas) | Candidate cardiovascular disease genes Enzymes FDA approved drug targets Predicted intracellular proteins Predicted secreted proteins RAS pathway related proteins
| | | | | Tissue enriched |
PLA2G4A | Phospholipase A2, group IVA (cytosolic, calcium-dependent) | Disease related genes Enzymes FDA approved drug targets Predicted intracellular proteins RAS pathway related proteins
| | | | | Mixed |
PLAT | Plasminogen activator, tissue | Cancer-related genes Candidate cardiovascular disease genes Disease related genes Enzymes FDA approved drug targets Plasma proteins Predicted secreted proteins
| | | | | Mixed |
PLG | Plasminogen | Cancer-related genes Candidate cardiovascular disease genes Disease related genes Enzymes FDA approved drug targets Plasma proteins Predicted secreted proteins
| | | | | Tissue enriched |
PNLIP | Pancreatic lipase | Enzymes FDA approved drug targets Plasma proteins Predicted secreted proteins
| | | | | Tissue enriched |
POLA1 | Polymerase (DNA directed), alpha 1, catalytic subunit | Enzymes FDA approved drug targets Predicted intracellular proteins
| | | | | Expressed in all |
POLB | Polymerase (DNA directed), beta | Enzymes FDA approved drug targets Plasma proteins Predicted intracellular proteins
| | | | | Expressed in all |
PRDX5 | Peroxiredoxin 5 | Enzymes FDA approved drug targets Mitochondrial proteins Plasma proteins Predicted intracellular proteins
| | | | | Expressed in all |
PRKAA1 | Protein kinase, AMP-activated, alpha 1 catalytic subunit | Enzymes FDA approved drug targets Predicted intracellular proteins
| | | | | Expressed in all |
PRKAB1 | Protein kinase, AMP-activated, beta 1 non-catalytic subunit | FDA approved drug targets Predicted intracellular proteins
| | | | | Expressed in all |
PROC | Protein C (inactivator of coagulation factors Va and VIIIa) | Cancer-related genes Candidate cardiovascular disease genes Disease related genes Enzymes FDA approved drug targets Plasma proteins Predicted intracellular proteins Predicted secreted proteins
| | | | | Tissue enriched |
PROS1 | Protein S (alpha) | Candidate cardiovascular disease genes Disease related genes FDA approved drug targets Plasma proteins Predicted intracellular proteins Predicted membrane proteins Predicted secreted proteins
| | | | | Expressed in all |
PSMB1 | Proteasome (prosome, macropain) subunit, beta type, 1 | Enzymes FDA approved drug targets Plasma proteins Predicted intracellular proteins
| | | | | Expressed in all |
PSMB10 | Proteasome (prosome, macropain) subunit, beta type, 10 | Enzymes FDA approved drug targets Plasma proteins Predicted intracellular proteins
| | | | | Expressed in all |
PSMB8 | Proteasome (prosome, macropain) subunit, beta type, 8 | Disease related genes Enzymes FDA approved drug targets Plasma proteins Predicted intracellular proteins
| | | | | Expressed in all |
PSMB9 | Proteasome (prosome, macropain) subunit, beta type, 9 | Enzymes FDA approved drug targets Plasma proteins Predicted intracellular proteins
| | | | | Expressed in all |
PSMD1 | Proteasome (prosome, macropain) 26S subunit, non-ATPase, 1 | FDA approved drug targets Plasma proteins Predicted intracellular proteins Predicted membrane proteins Predicted secreted proteins
| | | | | Expressed in all |
PTGS1 | Prostaglandin-endoperoxide synthase 1 (prostaglandin G/H synthase and cyclooxygenase) | Cancer-related genes Enzymes FDA approved drug targets Predicted intracellular proteins Predicted secreted proteins
| | | | | Tissue enhanced |
PTGS2 | Prostaglandin-endoperoxide synthase 2 (prostaglandin G/H synthase and cyclooxygenase) | Cancer-related genes Enzymes FDA approved drug targets Predicted secreted proteins
| | | | | Tissue enhanced |
RARB | Retinoic acid receptor, beta | Cancer-related genes Disease related genes FDA approved drug targets Nuclear receptors Predicted intracellular proteins Transcription factors
| | | | | Mixed |
RARG | Retinoic acid receptor, gamma | Cancer-related genes FDA approved drug targets Nuclear receptors Plasma proteins Predicted intracellular proteins Transcription factors
| | | | | Tissue enhanced |
RRM1 | Ribonucleotide reductase M1 | Enzymes FDA approved drug targets Plasma proteins Predicted intracellular proteins
| | | | | Expressed in all |
RXRA | Retinoid X receptor, alpha | Cancer-related genes FDA approved drug targets Nuclear receptors Predicted intracellular proteins Transcription factors
| | | | | Expressed in all |
RYR1 | Ryanodine receptor 1 (skeletal) | Disease related genes FDA approved drug targets Plasma proteins Predicted intracellular proteins Predicted membrane proteins Transporters
| | | | | Tissue enriched |
SCN2A | Sodium channel, voltage-gated, type II, alpha subunit | Disease related genes FDA approved drug targets Predicted membrane proteins Transporters Voltage-gated ion channels
| | | | | Tissue enriched |
SERPINB2 | Serpin peptidase inhibitor, clade B (ovalbumin), member 2 | Cancer-related genes FDA approved drug targets Plasma proteins Predicted secreted proteins
| | | | | Tissue enhanced |
SERPINC1 | Serpin peptidase inhibitor, clade C (antithrombin), member 1 | Candidate cardiovascular disease genes Disease related genes FDA approved drug targets Plasma proteins Predicted secreted proteins
| | | | | Tissue enriched |
SERPIND1 | Serpin peptidase inhibitor, clade D (heparin cofactor), member 1 | Candidate cardiovascular disease genes Disease related genes FDA approved drug targets Plasma proteins Predicted secreted proteins
| | | | | Tissue enriched |
SI | Sucrase-isomaltase (alpha-glucosidase) | Disease related genes Enzymes FDA approved drug targets Plasma proteins Predicted membrane proteins
| | | | | Group enriched |
SIGMAR1 | Sigma non-opioid intracellular receptor 1 | Disease related genes FDA approved drug targets Predicted membrane proteins Predicted secreted proteins
| | | | | Expressed in all |
SIRT5 | Sirtuin 5 | FDA approved drug targets Predicted intracellular proteins
| | | | | Expressed in all |
SLC12A1 | Solute carrier family 12 (sodium/potassium/chloride transporter), member 1 | Disease related genes FDA approved drug targets Predicted membrane proteins Transporters
| | | | | Tissue enriched |
SLC12A3 | Solute carrier family 12 (sodium/chloride transporter), member 3 | Disease related genes FDA approved drug targets Plasma proteins Predicted membrane proteins Transporters
| | | | | Tissue enriched |
SLC12A5 | Solute carrier family 12 (potassium/chloride transporter), member 5 | FDA approved drug targets Predicted membrane proteins Transporters
| | | | | Tissue enriched |
SLC22A8 | Solute carrier family 22 (organic anion transporter), member 8 | FDA approved drug targets Predicted membrane proteins Transporters
| | | | | Tissue enriched |
SLC5A2 | Solute carrier family 5 (sodium/glucose cotransporter), member 2 | Disease related genes FDA approved drug targets Predicted membrane proteins Transporters
| | | | | Tissue enriched |
SLC6A1 | Solute carrier family 6 (neurotransmitter transporter), member 1 | FDA approved drug targets Predicted intracellular proteins Predicted membrane proteins Transporters
| | | | | Group enriched |
SMS | Spermine synthase | Disease related genes Enzymes FDA approved drug targets Predicted intracellular proteins
| | | | | Expressed in all |
SNAP25 | Synaptosomal-associated protein, 25kDa | FDA approved drug targets Predicted intracellular proteins Transporters
| | | | | Tissue enriched |
SOAT1 | Sterol O-acyltransferase 1 | Enzymes FDA approved drug targets Predicted membrane proteins
| | | | | Tissue enriched |